Insilico Medicine's experimental lung drug rentosertib was associated with lower predicted biological age across six proteomic aging clocks in a 12-week Phase 2a analysis, creating an early human signal at the intersection of idiopathic pulmonary fibrosis (IPF) and aging. The finding does not show that participants became younger or that the drug extends life.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.